Pay in 4 interest-free payments of $6.42 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
Others resort to compounded forms from licensed pharmacies to make it less expensive
Retatrutide, a GIP, GLP-1 and Glucagon Receptor Agonist, for People With Type 2 Diabetes: A Randomised, Double-Blind, Placebo and Active-Controlled, Parallel-Group, Phase 2 Trial
What Are Safer Alternatives to Retatrutide
In the phase 3 ATTAIN-2 trial , adults with obesity and type 2 diabetes who took orforglipron lost an average of 5.1%9.6% over 72 weeks, compared to 2.5% in those who took a placebo
The semaglutide-to-tirzepatide conversion chart provides dosing equivalencies for a smooth transition
US$ 23.44
US$ 21.53
US$ 23.36
US$ 27.75
US$ 22.74
US$ 25.93
US$ 23.28
